Keryx Biopharma - KERX
- Creatore Discussione acqua+
- Data di Inizio
acqua+
ONDA NITRICA
Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
http://finance.yahoo.com/news/Keryx-Biopharmaceuticals-prnews-14982373.html?.v=1
http://finance.yahoo.com/news/Keryx-Biopharmaceuticals-prnews-14982373.html?.v=1
magolibero
..se la sà gira..
doctor NO
NO nel DNA
Data
8:29am EDT
Keryx Biopharmaceuticals announced multiple presentations of preclinical data highlighting the anti-tumor effects of KRX-0401 (perifosine), the Company's lead anti-cancer compound. Perifosine, as a single agent, inhibits neuroblastoma tumor cell growth in in vitro and in vivo preclinical models. In vitro studies in neuroblastoma cell lines indicate that perifosine treatment induced inhibition of Akt phosphorylation, and decreases of cell survival. In vivo studies of perifosine treatment led to significant increases in neuroblastoma tumor bearing mouse survival. In summary, Investigators conclude that the data indicates that as a single agent, perifosine targets activation of Akt in neuroblastoma cells and xenografts, and significantly inhibits tumor growth. Targeting breast cancer stem cells through inhibition of PI3-K/Akt/B-catenin signaling. According to Investigators, the data suggests that the PI3-K/Akt/ B-catenin pathway plays an important role in mammary stem cell self-renewal and that targeting of cancer stem cells through inhibition of this signaling pathway represents a rational therapeutic strategy. Potent antitumor effects of nab-rapamycin (ABI-009) in combination with kinase inhibitors Erlotinib and Perifosine According to Investigators, this study confirmed results by Cirstea et al. that dual inhibition of the Akt pathway by rapamycin (ABI-009) and Perifosine induces synergistic anti-tumor activity in multiple myeloma.
magolibero
..se la sà gira..
dopo 1h30'
738mila pezzi ..e 0,21 non li supera
738mila pezzi ..e 0,21 non li supera
magolibero
..se la sà gira..
ieri 21Apr 3presentazioni3 e una il giorno precedente
http://www.tradingmarkets.com/.site/news/Stock News/2282608/
April 21, 2009 -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX | Quote | Chart | News | PowerRating) today announced multiple presentations of preclinical data highlighting the anti-tumor effects of KRX-0401 (perifosine), the company's lead anti-cancer compound, at the American Association of Cancer Research (AACR) Annual Meeting, being held in Denver, Colorado.
Abstracts selected for presentation today, Tuesday, April 21, 2009, are as follows:
Abstract 3205:
Perifosine, as a single agent, inhibits neuroblastoma tumor cell growth in in vitro and in vivo preclinical models.
Author(s): Zhijie Li, Fei Tan, Jenna Tong, Amy McKee, Carol Thiele. National Cancer Inst., Bethesda, MD
Time/location: 8:00 AM - 12:00 PM, Hall B-F, Poster Section 10, # 13
Abstract Summary: In vitro studies in neuroblastoma cell lines indicate that perifosine treatment induced inhibition of Akt phosphorylation, and decreases of cell survival. In vivo studies of perifosine treatment led to significant increases in neuroblastoma tumor bearing mouse survival. In summary, Investigators conclude that the data indicates that as a single agent, perifosine targets activation of Akt in neuroblastoma cells and xenografts, and significantly inhibits tumor growth.
Abstract 4794:
Targeting breast cancer stem cells through inhibition of PI3-K/Akt/B-catenin signaling
Author(s): Korkaya Hasan, Amanda K. Paulson, Max S. Wicha. University of Michigan, Ann Arbor, MI
Time/location: 3:10 - 3:25 PM, Room 205-207, Colorado Convention Ctr.
Session Title: Cancer Stem Cell Approaches for Identification and Targeting
Abstract Summary: According to Investigators, the data suggests that the PI3-K/Akt/ B-catenin pathway plays an important role in mammary stem cell self-renewal and that targeting of cancer stem cells through inhibition of this signaling pathway represents a rational therapeutic strategy.
Abstract 4576:
Potent antitumor effects of nab-rapamycin (ABI-009) in combination with kinase inhibitors Erlotinib and Perifosine
Author(s): Neil Desai, Osmond D'Cruz, Vuong Trieu. Abraxis BioScience, LLC., Los Angeles, CA
Time/location: 1:00 PM - 5:00 PM, Hall B-F, Poster Section 33, # 9
Abstract Summary: According to Investigators, this study confirmed results by Cirstea et al. that dual inhibition of the Akt pathway by rapamycin (ABI-009) and Perifosine induces synergistic anti-tumor activity in multiple myeloma (AACR Annual Meeting 2008, #4181). The synergy of these combinations confirms Investigators' hypothesis that rapamycin is active only on mTORC1 and inhibition of mTORC2 by either Erlotinib or Perifosine is necessary to achieve complete shutdown of mTOR signaling pathway.
The following abstract was presented yesterday:
Abstract 2822:
Evidence implicating Bim activation/induction in potentiation of PI3K/Akt inhibitor-mediated apoptosis in human leukemia cells
Author(s): Mohamed Rahmani, Anh Anderson, Joseph Reza Habibi, Timothy Ryan Crabtree, Hisashi Harada, Paul Dent, Steven Grant. VCU Massey Cancer Ctr., Richmond, VA Abstract Summary: Investigators conclude that findings from this study suggest that Bim activation plays a key role in potentiating the antineoplastic activity of PI3K/Akt inhibitors in human leukemia cells, and raise the possibility that this phenomenon may contribute to synergistic interactions between PI3K/Akt and MEK1/2 inhibitors in such cells.
All abstracts can be viewed at www.aacr.org. A copy of the posters presented at AACR may be obtained by contacting the Company.
magolibero
..se la sà gira..
merita un ricordino
After Hours: 0.31990.0299 (10.31%) 7:36PM ET
Last Trade:0.29 Change:0.1289 (80.01%)
Prev Close:0.16 Open:0.171y Target Est:3.00
Volume: 6,911,794 Avg Vol (3m):582,800 Market Cap:13.87M
oggi scambia anche nel pre-market
30mila pezzi ad un ora dalla apertura
..
..
